Download PDF
Thromb Haemost 1992; 68(05): 583-588
DOI: 10.1055/s-0038-1646321
Original Article
Schattauer GmbH Stuttgart

Cigarette Smoking Increases Thromboxane A2 Formation without Affecting Platelet Survival in Young Healthy Females

Annika Dotevall
1   The Department of Medicine, Östra Hospital, University of Göteborg, Göteborg, Sweden
,
Christina Rångemark
2   The Department of Clinical Physiology, Sahlgren's Hospital, University of Göteborg, Göteborg, Sweden
,
Elsa Eriksson
3   The Laboratory of Biorheology, Sahlgren's Hospital, University of Göteborg, Göteborg, Sweden
,
Jack Kutti
1   The Department of Medicine, Östra Hospital, University of Göteborg, Göteborg, Sweden
,
Hans Wadenvik
1   The Department of Medicine, Östra Hospital, University of Göteborg, Göteborg, Sweden
,
Åke Wennmalm
2   The Department of Clinical Physiology, Sahlgren's Hospital, University of Göteborg, Göteborg, Sweden
› Author Affiliations
Further Information

Publication History

Received 08 November 1991

Accepted after revision 09 June 1992

Publication Date:
04 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Smoking is a risk factor for the development of atherosclerotic cardiovascular disease, in men as well as in women. An increased urinary excretion of the thromboxane metabolite 2,3-dinor-thromboxane B2 (Tx-M) has been observed in smokers of both genders, suggesting that cigarette smoking may facilitate cardiovascular disease via an action on the platelets. The present study addressed the hypothesis that the increased Tx-M excretion in female smokers reflects a true facilitation of platelet reactivity in vivo, rather than an increased destruction of the platelets. In healthy female volunteers (aged 20–46 years, 18 smokers and 17 non-smokers) platelet life-span and indices of platelet activity were determined, together with plasma levels of plasminogen activator inhibitor-1 (PAI-1), fibrinogen, peripheral blood cell counts and hematocrit. The urinary excretion of Tx-M was higher in smokers than in non-smokers (361 vs. 204 pg/mg creatinine, respectively, p <0.05), while plasma and urinary β-thromboglobulin, plasma platelet factor 4, platelet mean life-span and platelet production rate did not differ between the groups. PAI-1 activity, white blood cell count and hematocrit were higher in smokers than in non-smokers (p <0.05). These data indicate that smoking facilitates platelet formation of thromboxane A2 without affecting platelet survival; i.e. it increases the activity of platelets without affecting their viability to a measurable extent. Such an increase in platelet activity, operating in parallel to a reduced fibrinolytic activity and a higher hematocrit and white blood cell count, may play an etiological role in smoking-induced cardiovascular disease in women.

 

  • REFERENCES

  • 1 Perlman JA, Wolf PH, Ray R, Lieberknecht G. Cardiovascular risk factors, premature heart disease and all-cause mortality in a cohort of Northern California women. Am J Obstet Gynecol 1988; 158: 1568-1574
    CrossrefPubMedGoogle Scholar
  • 2 Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: A 26-year follow-up of the Framingham population. Am Heart J 1986; 111: 383-390
    CrossrefPubMedGoogle Scholar
  • 3 Goldbaum GM, Kendrick JS, Hogelin GC, Gentry EM. The behavioral risk factor surveys group. The relative impact of smoking and oral contraceptive use on women in the United States. JAMA 1987; 258: 1339-1342
    CrossrefPubMedGoogle Scholar
  • 4 LaVecchia C, Franceschi S, Decarli A, Pampallona S, Tognoni G. Risk factors for myocardial infarction in young women. Am J Epidemiol 1987; 125: 832-843
    CrossrefPubMedGoogle Scholar
  • 5 Freedman DS, Gruchow HW, Walker JA, Jacobsen SJ, Anderson AJ, Sobocinski KA, Barboriak JJ. Cigarette smoking and non-fatal myocardial infarction in women: is the relation independent of coronary artery disease? Br Heart J. 1989; 62: 273-280
    PubMedGoogle Scholar
  • 6 Gramenzi A, Gentile A, Fasoli M, D'Avanzo B, Negri E, Parazzini F, La Vecchia C. Smoking and myocardial infarction in women: a case control study from northern Italy. J Epidemiol Community Health 1989; 43: 214-217
    CrossrefPubMedGoogle Scholar
  • 7 Rosenberg L, Kaufman DW, Helmrich SP, Miller DR, Stolley PD, Shapiro S. Myocardial infarction and cigarette smoking in women younger than 50 years of age. JAMA 1985; 253: 2965-2969
    CrossrefPubMedGoogle Scholar
  • 8 Wilett WC, Green A, Stampfer MJ, Speizer FE, Colditz GA, Rosner B, Monson RR, Stason W, Hennekens CH. Relative and absolute excess risk of coronary heart disease among women who smoke cigarettes. N Engl J Med 1987; 317: 1303-1309
    CrossrefPubMedGoogle Scholar
  • 9 Fielding JE. Smoking and women. Tragedy of the majority. N Engl J Med 1987; 317: 1343-1345
    CrossrefPubMedGoogle Scholar
  • 10 Berman A. Facts on women and smoking. JAMWA 1989; 44: 55
    PubMedGoogle Scholar
  • 11 Lapidus L, Bengtsson C, Lindquist O, Sigurdsson JA, Rafnsson V. Smoking - a risk factor for cardiovascular disease in women? Scand J Prim Health Care. 1986; 4: 219-224
    PubMedGoogle Scholar
  • 12 Kutti J. Smoking, platelet reactivity and fibrinogen. In: Tobacco Smoking and Atherosclerosis. Diana JN. (ed) Plenum Press, New York: 1990. pp 129-134
    Google Scholar
  • 13 Mustard JF, Murphy EA. Effect of smoking on blood coagulation and platelet suvival in man. Br Med J 1963; I: 846-849
    PubMedGoogle Scholar
  • 14 Fuster V, Chesebro JH, Frye RL, Elveback LR. Platelet survival and the development of coronary artery disease in the young adult: Effects of cigarette smoking, strong family history and medical therapy. Circulation 1981; 63: 546-551
    CrossrefPubMedGoogle Scholar
  • 15 Steele PP, Weily HS, Davies H, Genton E. Platelet function studies in coronary artery disease. Circulation 1973; 48: 1194-1200
    CrossrefPubMedGoogle Scholar
  • 16 Ritchie J, Harker L. Platelet and fibrinogen survival in coronary atherosclerosis. Response to medical and surgical therapy. Am J Cardiol 1977; 39: 595-598
    CrossrefPubMedGoogle Scholar
  • 17 Nowak J, Murray JJ, Oates JA, FitzGerald GA. Biochemical evidence of a chronic abnormality in platelet and vascular function in healthy individuals who smoke cigarettes. Circulation 1987; 76: 06-14
    CrossrefPubMedGoogle Scholar
  • 18 Murray JJ, Nowak J, Oates JA, FitzGerald GA. Platelet-vessel wall interactions in individuals who smoke cigarettes. In: Tobacco Smoking and Atherosclerosis. Diana JN. (ed) Plenum Press, New York: 1990. pp 189-198
    Google Scholar
  • 19 Rångemark C, Benthin G, Granström EF, Persson L, Winell S, Wennmalm Å. Tobacco use and urinary excretion of thromboxane A2 and prostacyclin metabolites in women stratified by age. Circulation. In press
    PubMedGoogle Scholar
  • 20 Wennmalm A, Benthin G, Granström EF, Persson L, Petersson AS, Winell S. Relation between tobacco use and urinary excretion of thromboxane A2 and prostacyclin metabolites in young men. Circulation. 1991; 83: 1698-1704
    PubMedGoogle Scholar
  • 21 Wadenvik H, Kutti J. The in vivo kinetics of 111In- and 51Cr-labelled platelets: a comparative study using both stored and fresh platelets. Br J Haematol. 1991; 78: 523-528
    PubMedGoogle Scholar
  • 22 Panel on diagnostic application of radioisotopes in hematology, ICSH Recommended methods for radioisotope platelet survival studies. Blood 1977; 50: 1137-1144
    PubMedGoogle Scholar
  • 23 Nadler SB, Hidalgo JU, Bloch T. Prediction of blood volume in normal human adults. Surgery 1962; 51: 224-232
    PubMedGoogle Scholar
  • 24 Kutti J, Safai-Kutti S. In vitro labelling of platelets: an experimental study on healthy asplenic subjects using two different incubation media. Br J Haematol 1975; 31: 57-64
    PubMedGoogle Scholar
  • 25 Kutti J, Safai-Kutti S, Sigvaldasson A, Edgar B, Lundborg P. The effect of acetylsalicylic acid in 3 different formulations on in vitro and in vivo platelet function tests. Scand J Haematol 1984; 32: 379-384
    PubMedGoogle Scholar
  • 26 Vermylen J, De Vreker RA, Verstraete M. A rapid enzymatic method for assay of fibrinogen fibrin polymerization time (FPT-test). Clin Chim Acta 1963; 8: 418-424
    CrossrefPubMedGoogle Scholar
  • 27 Mielke CH, Kaneshiro MM, Maher IA, Weiner JM, Rapaport SI. The standardized normal Ivy bleeding time and its prolongation by aspirin. Blood 1969; 34: 204-215
    CrossrefPubMedGoogle Scholar
  • 28 Eriksson E, Rånby M, Gyzander E, Risberg B. Determination of plasminogen activator inhibitor in plasma using t-PA and a chromogenic single-point poly-d-lysine stimulated assay. Thromb Res 1988; 50: 091-101
    CrossrefPubMedGoogle Scholar
  • 29 Vicari AM, Margonato A, Macagni A, Luoni R, Seveso MP, Vicedomini G, Pozza G. Effects of acute smoking on the hemostatic system in humans. Clin Cardiol 1988; 11: 538-540
    CrossrefPubMedGoogle Scholar
  • 30 Gjerløff-Schmidt K, Waever Rasmussen J. Acute platelet activation induced by smoking. In vivo and ex vivo studies in humans. Thromb Haemostas 1984; 51: 279-282
    PubMedGoogle Scholar
  • 31 Lassila R, Laustiola KE. Physical exercise provokes platelet desensiti-zation in men who smoke cigarettes - Involvement of sympathoad-renergic mechanisms - A study of monozygotic twin pairs discordant for smoking. Thromb Res 1988; 51: 145-155
    CrossrefPubMedGoogle Scholar
  • 32 Dotevall A, Kutti J, Teger-Nilsson AC, Wadenvik H, Wilhelmsen L. Platelet reactivity, fibrinogen and smoking. Eur J Haematol 1987; 38: 55-59
    PubMedGoogle Scholar
  • 33 Toivanen J, Ylikorkala O, Viinikka L. Effects of smoking and nicotine on human prostacyclin and thromboxane production in vivo and in vitro. Toxicol Appl Pharmacol 1986; 82: 301-306
    CrossrefPubMedGoogle Scholar
  • 34 Krause FJ. Thromboxane concentrations in arterial blood of cigarette smokers and hypertensive subjects. In: Prostaglandins in Clinical Research. Alan R Liss Inc, New York. 1987; pp 155-163
    PubMedGoogle Scholar
  • 35 Kutti J, Safai-Kutti S, Svärdsudd K, Swedberg K, Wadenvik H. Plasma levels of platelet factor 4 in patients admitted to a coronary care unit. Scand J Haematol 1981; 26: 235-240
    PubMedGoogle Scholar
  • 36 Pumphrey CW, Dawes J. Plasma beta-thromboglobulin as a measure of platelet activity. Effect of risk factors and findings in ischemic heart disease and after acute myocardial infarction. Am J Cardiol 1982; 50: 1258-1261
    CrossrefPubMedGoogle Scholar
  • 37 Musumeci V, Rosa A, Caruso A, Zappacosta B, Turtinelli F, Zuppi C. Urine beta-thromboglobulin concentration or beta-thromboglobu-lin/creatinine ratio in single voided urine samples cannot be reliably used to estimate quantitative beta-thromboglobulin excretion. Thromb Haemostas 1986; 55: 2-5
    PubMedGoogle Scholar
  • 38 Heaton WAL. Indium-111 (111In) and Chromium-51 (51Cr) labeling of platelets. Are they comparable? Transfusion. 1986; 26: 16-19
    PubMedGoogle Scholar
  • 39 Mileikowsky GN, Nadler JL, Huey F, Francis R, Roy S. Evidence that smoking alters prostacyclin formation and platelet aggregation in women who use oral contraceptives. Am J Obstet Gynecol 1988; 159: 1547-1552
    CrossrefPubMedGoogle Scholar
  • 40 Wilhelmsen L, Svärdsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501-505
    CrossrefPubMedGoogle Scholar
  • 41 Kannel WB, D'Agostino RB, Belanger AJ. Fibrinogen, cigarette smoking and risk of cardiovascular disease: Insights from the Framingham study. Am Heart J 1987; 113: 1006-1010
    CrossrefPubMedGoogle Scholar
  • 42 Yarnell JWG, Baker IA, Sweetnam PM, Bainton D, O'Brien JR, Whitehead PJ, Elwood PC. Fibrinogen, viscosity and white blood cell count are major risk factors for ischemic heart disease. The Caerphilly and Speedwell Collaborative Heart Disease Studies. Circulation 1991; 83: 836-844
    CrossrefPubMedGoogle Scholar
  • 43 Ernst E, Matrai A. Abstension from chronic cigarette smoking normalizes blood rheology. Atherosclerosis 1987; 64: 75-77
    CrossrefPubMedGoogle Scholar
  • 44 Yarnell JWG, Sweetnam PM, Rogers S, Elwood PC, Bainton D, Baker IA, Eastham R, O'Brien JR, Etherington MD. Some long term effects of smoking on the hemostatic system: a report from the Caerphilly and Speedwell Collaborative Surveys. J Clin Pathol 1987; 40: 909-913
    CrossrefPubMedGoogle Scholar
  • 45 Balleisen L, Bailey J, Epping PH, Schulte H, van de Loo J. Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population: I. Baseline data on the relation to age, gender, body-weight, smoking, alcohol, pill-using and menopause. Thromb Haemostas 1985; 54: 475-479
    PubMedGoogle Scholar
  • 46 Lee AJ, Smith WCS, Lowe GDO, Tunstall-Pedoe H. Plasma fibrinogen and coronary risk factors: the Scottish Heart Health Study. J Clin Epidemiol 1990; 43: 913-919
    CrossrefPubMedGoogle Scholar
  • 47 Feher MD, Rampling MW, Brown J, Robinson J, Richmond W, Cholerton S, Bain BJ, Sever PS. Acute changes in atherogenic and thrombogenic factors with cessation of smoking. J R Soc Med 1990; 83: 146-148
    CrossrefPubMedGoogle Scholar
  • 48 Hamsten A, Wiman B, deFaire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313: 1557-1563
    CrossrefPubMedGoogle Scholar
  • 49 Nilsson T, Johnson O. The extrinsic fibrinolytic system in survivors of myocardial infarction. Thromb Res 1987; 48: 621-630
    CrossrefPubMedGoogle Scholar
  • 50 Hamsten A, deFaire U, Walldius G, Dahlén G, Szamosi A, Landou C, Blombäck M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2: 3-9
    PubMedGoogle Scholar
  • 51 Sundell IB, Nilsson TK, Rånby M, Hallmans G, Hellsten G. Fibrinolytic variables are related to age, sex, blood pressure and body build measurements: a cross sectional study in Norsjö, Sweden. J Clin Epidemiol 1989; 42: 719-723
    CrossrefPubMedGoogle Scholar
  • 52 Landin K, Stigendal L, Eriksson E, Krotkiewski M, Risberg B, Tengborn L, Smith U. Abdominal obesity is associated with an impaired fibrinolytic capacity and elevated plasminogen activator inhibitor-1. Metabolism 1990; 39: 1044-1048
    CrossrefPubMedGoogle Scholar
  • 53 Olofsson BO, Dahlén G, Nilsson TK. Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease. Eur Heart J 1989; 10: 77-82
    CrossrefPubMedGoogle Scholar